Join        Login             Stock Quote

Arrowhead Research (ARWR), Shire To Develop Peptide-Targeted Therapeutics; Shares Jump

 December 18, 2012 09:13 AM

(By Balaseshan) Arrowhead Research Corp. (NASDAQ: ARWR), a clinical stage targeted therapeutics company, said it has entered into collaboration and license agreement with Shire AG (NASDAQ: SHPG) to develop peptide-targeted therapeutics. Following the news, shares soared 10% in premarket.

The company and Shire to develop and commercialize targeted peptide-drug conjugates (PDCs) by utilizing Arrowhead's human-derived Homing Peptide platform and Shire's therapeutic payloads.

Arrowhead will receive research funding and could be eligible for development, regulatory, and commercialization milestone payments of up to $32.8 million for each development candidate, plus additional milestone payments for a second indication, and royalties on worldwide sales. Additional financial terms of the agreement were not disclosed.

[Related -Analysts' Upgrades And Downgrades: GRPN, GSK, JOY, RVBD, SHPG, LAMR, EIX, BSFT]

Under the agreement, Arrowhead will identify peptides that selectively bind and internalize in an undisclosed tissue type and that are capable of delivering a therapeutic payload to that tissue.

The company will receive funding for its internal and external research program-related costs and Shire will have an option to obtain an exclusive license to develop and commercialize a therapeutic agent targeted by the designated peptides and be responsible for clinical development and commercialization of products arising from the collaboration.

[Related -Shire (SHPG): FDA Accepts Filing For Review Of Attention-Deficit/Hyperactivity Disorder Drug]

Arrowhead's Homing Peptides comprise a library of human-derived peptide sequences that have been shown to localize to specific tissues in the human body. This platform enables the creation of guided therapeutics that specifically target tissues of interest while sparing off-target issues.

ARWR closed Monday's regular session at $2.50. The stock has been trading between $2.05 and $7.31 for the past 52 weeks.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageThe S&P 500’s Worrisome Downturn In Drawdown

Last Friday I reviewed some of the bearish signals that were casting dark shadows across the US stock read on...

article imageADP: Private-Sector Employment Rises A Solid 200k In September

The pace of growth for private-sector employment picked up in September, according to this morning’s ADP read on...

article imageTreasury Market’s Inflation Expectations Tumble

The odds for a Fed rate hike are falling like a stone, or so it appears based on the implied inflation read on...

article imageEmerging Market Stocks: Last Week’s Red-Ink Leader

Value investors on the lookout for bargains have recently been eyeing up the battered corner of emerging read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.